LPCAT1

Across TCGA pan-cancer cohorts, LPCAT1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LPCAT1 data layer compared with 26 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher LPCAT1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated LPCAT1 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

CCRCC, UCEC, and PDAC are the cancer types where LPCAT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.731	0.958	<.001	36	view →
UCEC	DFS	Quartile	All	0.850	1.000	.032	4	view →
PDAC	DFS	Tertile	All	0.323	0.474	.049	2	view →
GBM	OS	Tertile	All	0.676	0.907	.042	1	view →
HNSC	OS	Median	III,IV	1.000	0.948	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LPCAT1–CCRCC (OS)

Open the CCRCC breakdown →